Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 5,000 Shares

Alkermes plc (NASDAQ:ALKS) EVP Craig Hopkinson sold 5,000 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $30.00, for a total value of $150,000.00. Following the transaction, the executive vice president directly owned 61,740 shares of the company’s stock, valued at $1,852,200. This represents a 7.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Alkermes Trading Up 0.8%

NASDAQ:ALKS traded up $0.24 during mid-day trading on Thursday, reaching $29.60. 2,311,441 shares of the stock were exchanged, compared to its average volume of 1,918,768. The business has a fifty day moving average price of $29.28 and a 200 day moving average price of $29.05. Alkermes plc has a 1-year low of $25.17 and a 1-year high of $36.45. The firm has a market capitalization of $4.89 billion, a PE ratio of 14.65 and a beta of 0.48.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.08. The company had revenue of $394.19 million during the quarter, compared to analyst estimates of $355.23 million. Alkermes had a net margin of 22.27% and a return on equity of 21.81%. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 EPS. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. On average, sell-side analysts forecast that Alkermes plc will post 1.31 earnings per share for the current year.

Hedge Funds Weigh In On Alkermes

Institutional investors and hedge funds have recently bought and sold shares of the business. Assetmark Inc. boosted its holdings in shares of Alkermes by 933.8% during the third quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 747 shares during the period. Armstrong Advisory Group Inc. purchased a new stake in Alkermes in the 2nd quarter worth approximately $29,000. Johnson Financial Group Inc. acquired a new stake in shares of Alkermes during the 3rd quarter valued at $31,000. Hantz Financial Services Inc. boosted its stake in shares of Alkermes by 395.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company’s stock valued at $37,000 after buying an additional 989 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Alkermes during the 2nd quarter valued at $49,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on ALKS. Wells Fargo & Company dropped their price target on Alkermes from $42.00 to $37.00 and set an “overweight” rating on the stock in a report on Thursday, November 13th. Wall Street Zen cut Alkermes from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 9th. Jefferies Financial Group set a $56.00 target price on Alkermes and gave the company a “buy” rating in a report on Tuesday, October 28th. HC Wainwright reiterated a “neutral” rating on shares of Alkermes in a research report on Wednesday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.69.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.